reconstitution is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-08-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Melanotan II; MT-II; N-acetyl-norleucyl-cyclo[Asp-His-D-Phe-Arg-Trp-Lys] amide | Naming follows peptide convention; the numeral distinguishes it from melanotan-1 |
| Molecular formula | C50H69N15O9 | Includes the lactam bridge; no counter-ion assumed |
| Monoisotopic mass | 1023.53 Da | Free base; salts and counter-ions shift the observed value |
| Appearance | White to off-white lyophilised powder | Batch-to-batch colour variation is not itself proof of impurity |
| Typical analytical method | RP-HPLC purity determination with ESI-MS identity confirmation | Retention time alone does not establish sequence identity |
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Freeze-dried melanotan-2 is normally kept as a desiccated powder at minus twenty degrees Celsius or lower, shielded from light and moisture. Peptides of this size degrade through hydrolysis, oxidation and deamidation, and each pathway accelerates as temperature and water activity rise. Repeated freeze-thaw cycles promote aggregation and loss of material, so aliquoting a stock solution before freezing is standard laboratory practice. Once dissolved, the solution is markedly less stable than the powder. In laboratory work, solutions are generally refrigerated and used within days rather than kept for months.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or oxidised impurities. Mass spectrometry, most often coupled to liquid chromatography, confirms molecular mass and detects substitutions that chromatography alone may miss. Amino acid analysis and peptide mapping supply additional structural evidence, while nuclear magnetic resonance is reserved for full structural confirmation. Laboratories that examine samples sold online report wide variation in actual content, with some vials containing little or none of the labelled material.
As a bifunctional molecule, glycine reacts with many reagents. These can be classified into N-centered and carboxylate-center reactions. Glycine functions as a bidentate ligand for many metal ions, forming amino acid complexes. Representative complexes include iron glycinate, copper glycinate, and zinc glycinate. With acid chlorides, glycine converts to the amidocarboxylic acid, such as hippuric acid and acetylglycine. With nitrous acid, one obtains glycolic acid (van Slyke determination). With methyl iodide, the amine becomes quaternized to give trimethylglycine, a natural product:
=== Degradation of collagen === UV exposure would also lead to the activation of receptors for epidermal growth factor, IL-1, and TNF-α in keratinocytes and fibroblasts, which then activate signaling kinases throughout the skin via an unknown mechanism. The nuclear transcription factor activator protein, AP-1, which controls the transcription of matrix metalloproteinases (MMP), is expressed and activated. MMP-1 is a major metalloproteinase for collagen degradation. This entire process is aided by the presence of reactive oxygen species that inhibit protein-tyrosine phosphatases via oxidation, thereby resulting in the up-regulation of the above-mentioned receptors. Another transcription factor, NF-κB, which is also activated by UV light, increases the expression of MMP-9. The up-regulation of MMP can occur even after minimal exposure to UV; hence, exposure to UV radiation that is inadequate to cause sunburn can facilitate the degradation of skin collagen and, presumably, lead to eventual photoaging. Thus, collagen production is reduced in photoaged skin due to the process of constant degradation of collagen mediated by MMPs. In addition, the presence of damaged collagen would also downregulate the synthesis of new collagen. The impaired spreading and attachment of fibroblasts onto degraded collagen could be one of the contributing factors to the inhibition of collagen synthesis.
It was scheduled for release in August 2000 but canceled by the publisher Sierra Entertainment by this time. As Kudirka reported to id Software that he had been taken off a project, the studio referred him to the director Steven Spielberg. His company DreamWorks SKG had experimented with developing a personal computer follow-up to Medal of Honor but decided to work with an external partner instead. In May 2000, 2015 began work on what became Medal of Honor: Allied Assault. According to Kudirka, shortly before the release of Allied Assault, the studio director of development Vince Zampella began secretly meeting with Electronic Arts to establish a separate studio and take over most staff. Out of 27 employees, 20 had resigned by the end of the month. Zampella and Jason West founded Infinity Ward, which ultimately hired 22 former 2015 staffers. Rieke, who also left, said the development team had bonded but sought to work under a different management. In response to the departures, Kudirka filed a lawsuit against Zampella, which was settled when Activision bought a 30% stake in Infinity Ward. Allied Assault was a critical and commercial success, selling 1.5 million copies within a year. In January 2003, Vivendi Universal Games announced Men of Valor as 2015's next game for Windows and the Xbox. By March, 2015 had grown to 39 people, with John Whitmore as the new director of development. Men of Valor, released in 2004, was not as commercially successful as Allied Assault and subsequent attempts to pitch games to publishers failed.
=== Web search === Microsoft introduced Copilot Search in February 2023 under the name Bing Chat. Copilot Search provides AI-generated summaries. Generative AI features added to Google Search include AI Overviews in May 2024 and AI Mode in May 2025.
Shortly before World War II, Czechoslovakia ceased to exist. Its territory was divided into the Protectorate of Bohemia and Moravia, the newly declared Slovak State and the short-lived Republic of Carpathian Ukraine. While much of former Czechoslovakia came under the control of Nazi Germany, Hungarian forces swiftly overran the Carpathian Ukraine. Hungary annexed some areas (e.g., Southern Slovakia and Carpathian Ruthenia) in the autumn of 1938. Poland reclaimed Zaolzie previously annexed by the Czechs during the Polish-Soviet war in 1920. The Zaolzie region became part of Nazi Germany after the German invasion of Poland in September 1939. The German economy—burdened by heavy militarisation—urgently needed foreign currency. Setting up an artificially high exchange rate between the Czechoslovak koruna and the Reichsmark brought consumer goods to Germans (and soon created shortages in the Czech lands). Czechoslovakia had fielded a modern army of 35 divisions and was a major manufacturer of machine guns, tanks, and artillery, most of them assembled in the Škoda factory in Plzeň. Many Czech factories continued to produce Czech designs until converted to German designs. Czechoslovakia also had other major manufacturing companies. Entire steel and chemical factories were moved from Czechoslovakia and reassembled in Linz (which incidentally remains a heavily industrialized area of Austria).
Sources: en.wikipedia.org
Dialkylbiaryl phosphine ligands are air-stable solids. Many are available commercially. They often can be synthesized in from inexpensive starting materials. One pot protocols have been conducted on >10 kilograms (22 lb) scales.
The Moscow Jewelry Factory and the Jewellerprom produce jewelry. Other industries are located just outside Moscow, and some microelectronic industries are located in Zelenograd, including the company Ruselectronics. Gazprom, the world's largest extractor of natural gas and the largest Russian company, is headquartered in Moscow, along with other oil, gas, and electricity companies. Moscow contains the headquarters of many telecommunications and technology companies, including 1C, ABBYY, Beeline, Kaspersky Lab, Mail.Ru Group, MegaFon, MTS, Rambler&Co, Rostelecom, Yandex, and Yota. Some industry is being transferred out of Moscow to improve the city's ecological condition.
== Function == The antioxidant enzyme glutathione peroxidase 4 (GPX4) belongs to the family of glutathione peroxidases, which consists of 8 known mammalian isoenzymes (GPX1–8). GPX4 catalyzes the reduction of hydrogen peroxide, organic hydroperoxides, and lipid peroxides at the expense of reduced glutathione and functions in the protection of cells against oxidative stress. The oxidized form of glutathione (glutathione disulfide), which is generated during the reduction of hydroperoxides by GPX4, is recycled by glutathione reductase and NADPH/H+. GPX4 differs from the other GPX family members in terms of its monomeric structure, a less restricted dependence on glutathione as reducing substrate, and the ability to reduce lipid-hydroperoxides inside biological membranes. Inactivation of GPX4 leads to an accumulation of lipid peroxides, resulting in ferroptotic cell death. Mutations in GPX4 cause spondylometaphyseal dysplasia. In vitro studies suggest that GPX4 protects cells against cold-induced cell death. Therapy-resistant cancer cells in a high-mesenchymal state depend on a lipid peroxidase pathway to suppress ferroptosis, indicating a critical survival mechanism in this cellular context. Drug-tolerant persister cells exhibit a specific dependency on the lipid hydroperoxidase GPX4 for survival; inhibition of GPX4 induces ferroptotic cell death in these cells.
==== MeSH E05.478.550 – immunization ==== MeSH E05.478.550.520 – immunization, passive MeSH E05.478.550.520.050 – adoptive transfer MeSH E05.478.550.520.050.400 – immunotherapy, adoptive MeSH E05.478.550.545 – immunization schedule MeSH E05.478.550.550 – immunization, secondary MeSH E05.478.550.600 – immunotherapy, active MeSH E05.478.550.600.890 – vaccination MeSH E05.478.550.650 – mass immunization
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.
The natural hormone is a linear tridecapeptide that is rapidly degraded in circulation. Melanotan-2 is shortened, cyclised, N-terminally acetylated, and carries a D-amino acid substitution, all of which slow enzymatic breakdown.
No national medicines regulator has approved melanotan-2 for therapeutic or cosmetic use. In several jurisdictions it is treated as an unapproved prescription medicine, and its legal classification differs from country to country.
Only a small number of early-stage human studies have been reported, and most were limited in size and duration. No large late-stage program has established a general efficacy or safety profile. The evidence base is therefore thin compared with approved medicines.